Hadasit Medical Research Services and Development Ltd.

Yeda Research and Develpment & Co. Ltd

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Ben-Gurion University of the Negev Research and Development Authority

Hadasit Medical Research Services and Development Company

Protab Ltd.

Hadassa Medical Organization

Yaakov Naparstek

Rina Ulmansky

Yechezkel Kashi

Irun R Cohen

Ofer Mandelboim

Angel Porgador

Amiram Eldor

Chamutal Gur

Israel Vlodavsky

Yechezkel Barenholz

Yuval Avnir

Eli Moallem

Yechezkei Kashi

Shira Yair

The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

Method of treating type 1 diabetes by administering NKp46 polypeptide

The present invention relates to humanized antibodies that specifically bind a polypeptide comprising peptide-6 as denoted by SEQ ID NO. 15, that is an HSP65 derived peptide. More specifically, the invention relates to humanized anti-peptide-6 antibodies, compositions, methods and uses thereof for the treatment of immune-related disorders, specifically, inflammatory disorders such as arthritis, IBD, psoriasis, diabetes and MS. The invention further provides combined compositions and kit combining the humanized antibodies of the invention and at least one anti-inflammatory agent, as well as uses of the humanized antibodies in diagnostic kits and methods.

Humanized antibodies specific for HSP65-derived peptide-6 methods and uses thereof

The present invention relates to the use of Adenylyl Cyclase-Associated Protein (CAP1) as a target for immuno-modulation. More specifically, the invention relates to the use of compounds that interact and bind CAP1, specifically, anti-CAP1 antibodies, and/or to CAP1 molecule or any fragments thereof, for the treatment of immune-related disorders by modulation of the Th1/Th2 balance. The invention further provides screening method for immuno-modulatory compounds that interact with CAP1.

Adenylyl cyclase-associated protein (CAP1) and uses thereof as a target for immuno-modulation

Method of treating diabetes by administering an anti-NKp46 antibody

B-cell epitope peptides of HSP 65, particularly the peptides comprising the amino acid sequence substantially as denoted by SEQ ID: NOs. 1-5 and their biologically functional homologues and derivatives thereof. Also included are polyclonal and monoclonal antibodies directed against them and their compositions for passive immunization against inflammatory and autoimmune diseases and in the treatment of inflammatory and autoimmune diseases. Also encompassed are diagnostic uses of these antibodies, for identifying people at risk of developing arthritis or diabetes, and a method of monitoring progress of the disease conditions and disease prognosis.

B-cell epitope peptides of HSP 65, novel amino acid sequences, DNA encoding the amino acid sequences of said peptides, antibodies directed against said peptides and different uses thereof in the treatment of inflammatory and autoimmune diseases

The present invention provides the use of a glucocorticoid (GC) or of a GC derivative encapsulated in a liposome for the preparation of a pharmaceutical composition for the treatment of an inflammatory associated condition in a subject, provided that said condition is not associated with a neurodegenerative disease or disorder. A specific use concerns a liposomal formulation comprising methylprednisolone sodium hemisuccinate (MPS) for the treatment of rheumatoid arthritis.

Use of liposomal glucocorticoids for treating inflammatory states

B-cell epitope peptides of HSP 65, particularly the peptides comprising the amino acid sequence substantially as denoted by SEQ ID: Nos. 1-5 and their biologically functional homologues and derivatives thereof. Also included are polyclonal and monoclonal antibodies directed against them and their compositions for passive immunization against inflammatory and autoimmune diseases and in the treatment of inflammatory and autoimmune diseases. Also encompassed are diagnostic uses of these antibodies, for identifying people at risk of developing arthritis or diabetes, and a method of monitoring progress of the disease conditions and disease prognosis.

B-cell epitope peptides of HSP 65, DNA encoding said peptides, antibodies directed against said peptides and the different uses thereof in the treatment of inflammatory and autoimmune diseases

The invention is directed to a peptide comprising the amino acid sequence substantially as denoted by SEQ ID NO:1 and biologically functional homologues and derivatives thereof.

Amino acid sequences, DNA encoding the amino acid sequences, antibodies directed against such sequences and the different uses thereof

The invention is directed to a peptide, comprising the amino acid sequence substantially as denoted by SEQ ID NO:1 and biologically functional homologues and derivatives thereof.

B-cell epitope peptides of HSP 65

A method is disclosed for treating systemic lupus erythematosus in a mammalian subject, comprising administering to said subject an effective dose of at least one laminin peptide, or an analog or a derivative thereof. In one exemplary embodiment, the laminin peptide is selected from the group consisting of R38, and claimed R38 analogs and derivatives thereof including 5200, 5104, 5105, 5106, 5107, 5108, 5109, and 5110. The laminin peptides of the present invention may be prepared by known chemical synthetic methods or by biotechnological methods. Assays useful for the diagnosis of and following pathological activity course of systemic lupus erythematosus in patients suffering therefrom.

Peptides for the treatment of systemic lupus erythematosus

The invention provides an immunoassay reagent for the binding and detection of antibodies found in the urine of lupus disease patients, comprising extracellular matrix.

Lupus disease immunoassay methods

Heparanase activity in a patient may be inhibited by administering an effective heparanase-inhibiting amount of heparin or an effective chemically modified derivative of heparin which inhibits heparanase activity. Such derivatives are preferably N-desulfated, N-acetylated heparin or O-desulfated, N-acetylated heparin. By means of this invention, allograft rejection may be prevented or delayed and autoimmune diseases such as arthritis may be alleviated and treated.

Method for inhibiting heparanase activity

The invention relates to pharmaceutical compositions intended to decrease the incidence of tumor metastasis in patients who suffer from malignant diseases. The pharmaceutical compositions of the invention contain as active ingredient heparin or a suitable derivative thereof. Amongst suitable derivatives are N-desulfated and N-acetylated heparin. The dosage of the administered heparin or heparin derivative is quite critical and will generally be in the range of from 0.05 mg/kg/day to about 0.5 mg/kg/day. A preferred range is between about 0.1 mg/kg/day to about 0.5 mg/kg/day.

Growing community of inventors

Jerusalem, Israel

Yaakov Naparstek